Selected Publications

Hambardzumyan, D: Myeloid cell heterogeneity and their functions in pediatric high-grade gliomas. Brain tumors 2025: From Biology to Therapy; Neurobiology Center at the Nencki Institute, Warsaw, Poland June 2025.

Xing YL, Panovska D, Park JW, Grossauer S, Koeck K, Bui B, Nasajpour E, Nirschl JJ, Feng ZP, Cheung P, Habib P, Wei R, Wang J, Thomason W, Xiu J, Beck A, Weber K, Harter PN, Lim M, Mahaney K, Prolo LM, Grant GA, Ji X, Walsh KM, Mulcahy Levy JM, Hambardzumyan D, Petritsch CK : BRAF/MEK Inhibition Induces Cell State Transitions Boosting Immune Checkpoint Sensitivity in BRAFV600E -mutant Glioma bioRxiv Apr 2025 Notes: Accepted Preprint; doi: 10.1101/2023.02.03.526065.

Seblani M, Zannikou M, Duffy JT, Joshi T, Levine RN, Thakur A, Puigdelloses Vallcorba M, Horbinski CM, Miska J, Hambardzumyan D, Becher OJ, Balyasnikova IV: IL13RA2-integrated genetically engineered mouse model allows for CAR T cells targeting pediatric high-grade gliomas. Acta Neuropathol Commun 13(1): 69, Apr 2025.

Soni N, Rawat K, Chen Z, Giotti B, Di Mourio A, Hambardzumyan D, & Tsankov AM : Single-cell dissection of the genotype-immunophenotype relationship in glioblastoma. Brain Apr 2025 Notes: [Online ahead of print]; doi: 10.1093/brain/awaf129.

Li J, Shih LK, Markwell SM, Olson CL, Sullivan DP, Arvanitis C, Ross JL, Lam NG, Nuszen H, Hambardzumyan D, Becher OJ, Brat DJ: A clinically relevant model and method to study necrosis as a driving force in glioma restructuring and progression. Proc Natl Acad Sci U S A 122(1): e2416024122, Feb 2025.

Garcia-Fabiani MB, Haase S, Banerjee K, Zhu Z, McClellan BL, Mujeeb AA, Li Y, Tronrud CE, Varela ML, West MEJ, Yu J, Kadiyala P, Taher AW, Nunez FJ, Alghamri MS, Comba A, Mendez FM, Nicola Candia AJ, Salazar B, Nunez FM, Edwards MB, Qin T, Cartaxo RT, Niculcea M, Koschmann C, Venneti S, Vallcorba MP, Nasajpour E, Pericoli G, Vinci M, Kleinman CL, Jabado N, Chandler JP, Sonabend AM, DeCuypere M, Hambardzumyan D, Prolo LM, Mahaney KB, Grant GA, Petritsch CK, Welch JD, Sartor MA, Lowenstein PR, Castro MG: H3.3-G34R Mutation-Mediated Epigenetic Reprogramming Leads to Enhanced Efficacy of Immune Stimulatory Gene Therapy in Diffuse Hemispheric Gliomas. bioRxiv Feb 2025 Notes: Accepted Preprint; doi: 10.1101/2023.06.13.544658.

Zannikou MZ, Duffy JT, Procissi D, Najem H, Levine RN, Hambardzumyan D, Lee-Chang C, Leoni L, Zhang B, Heimberger AB, Miska J, Balyasnikova IV: A Bi-Specific T Cell-Engaging Antibody Shows Potent Activity, Specificity, and Tumor Microenvironment Remodeling in Experimental Syngeneic and Genetically Engineered Models of GBM bioRxiv Jan 2025 Notes: Accepted Preprint; doi: 10.1101/2024.12.18.628714.

Ross JL, Puigdelloses-Vallcorba M, Pinero G, Soni N, Thomason W, DeSisto J, Angione A, Tsankova NM, Castro MG, Schniederjan M, Wadhwani NR, Raju GP, Morgenstern P, Becher OJ, Green AL, Tsankov AM, Hambardzumyan D : Microglia and monocyte-derived macrophages drive progression of pediatric high-grade gliomas and are transcriptionally shaped by histone mutations. Immunity 57(11): 2669-87.e6, Nov 2024.

Read RD, Tapp ZM, Rajappa P, Hambardzumyan D: Glioblastoma microenvironment-from biology to therapy. Genes Dev 38(9-10): 360-379, Jun 2024.

Shi X, Lingerak R, Herting CJ, Ge Y, Kim S, Toth P, Wang W, Brown BP, Meiler J, Sossey-Alaoui K, Buck M, Himanen J, Hambardzumyan D, Nikolov DB, Smith AW, Wang B: Time-resolved live-cell spectroscopy reveals EphA2 multimeric assembly Science 382(6674): 1042-50, Dec 2023.